{"organizations": [], "uuid": "9f81c22887d213b78adbdaa6d26e2f65c70cec67", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180425.html", "section_title": "Archive News &amp; Video for Wednesday, 25 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-zogenix-announces-presentation-of/brief-zogenix-announces-presentation-of-new-efficacy-and-safety-data-from-its-firstpivotal-phase-3-clinical-trial-of-zx008-in-dravet-syndrome-idUSASC09XB1", "country": "US", "domain_rank": 408, "title": "BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.076, "site_type": "news", "published": "2018-04-25T20:08:00.000+03:00", "replies_count": 0, "uuid": "9f81c22887d213b78adbdaa6d26e2f65c70cec67"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-zogenix-announces-presentation-of/brief-zogenix-announces-presentation-of-new-efficacy-and-safety-data-from-its-firstpivotal-phase-3-clinical-trial-of-zx008-in-dravet-syndrome-idUSASC09XB1", "ord_in_thread": 0, "title": "BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "zogenix inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Zogenix Inc:\n* ZOGENIX ANNOUNCES PRESENTATION OF NEW EFFICACY AND SAFETY DATA FROM ITS FIRST PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME\n* ZOGENIX - PATIENTS ON ZX008 ACHIEVED SIGNIFICANT, CLINICALLY MEANINGFUL REDUCTION IN TOTAL SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T20:08:00.000+03:00", "crawled": "2018-04-26T20:06:44.000+03:00", "highlightTitle": ""}